Dopo l'orario di chiusura: 14.56 0.06 +0.41%

Ars Pharmaceuticals Inc (SPRY)

Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie

Ars Pharmaceuticals Inc (SPRY)

Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie

Neffy nasal spray: a game changer for asthma patients and epinephrine delivery? - Pharmaceutical Technology

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) to Post FY2024 Earnings of ($0.68) Per Share, William Blair Forecasts - MarketBeat

Dr. Thomas Casale discusses the impact of type 1 allergies and new treatments - KOKH FOX25

GoodRx Announces Lowest Discounted Cash Price at Retail Pharmacy Locations for neffy® (epinephrine nasal spray) - Business Wire

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 2.5% - MarketBeat

(SPRY) Technical Data - Stock Traders Daily

Nasal spray for severe allergies now available in the US By Investing.com - Investing.com Canada

Nasal spray for severe allergies now available in the US - Investing.com

ARS Pharmaceuticals updates manufacturing agreement terms - Investing.com

Nasal spray for severe allergies now available in the US - Investing.com India

ARS Pharmaceuticals Announces U.S. Availability of neffy® - GlobeNewswire

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis - Marketscreener.com

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis - StockTitan

Bank of New York Mellon Corp Increases Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat

ARS Pharmaceuticals (NASDAQ:SPRY) PT Raised to $25.00 - MarketBeat

Ars Pharmaceuticals CEO sells over $1.29 million in company stock By Investing.com - Investing.com Australia

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $140,000.00 in Stock - MarketBeat

Ars pharmaceuticals exec sells $140,000 in company stock By Investing.com - Investing.com Australia

ARS Pharmaceuticals exec sells over $1.29 million in company stock By Investing.com - Investing.com South Africa

Ars Pharmaceuticals CEO sells over $1.29 million in company stock By Investing.com - Investing.com South Africa

Ars pharmaceuticals exec sells $140,000 in company stock By Investing.com - Investing.com Canada

Ars pharmaceuticals exec sells $140,000 in company stock - Investing.com

ARS Pharmaceuticals exec sells over $1.29 million in company stock - Investing.com India

Ars Pharmaceuticals CEO sells over $1.29 million in company stock - Investing.com India

Ars Pharmaceuticals CEO sells over $1.29 million in company stock - Investing.com

Ars pharmaceuticals exec sells $140,000 in company stock By Investing.com - Investing.com UK

ARS Pharmaceuticals exec sells over $1.29 million in company stock - Investing.com

Ars Pharmaceuticals CEO sells over $1.29 million in company stock By Investing.com - Investing.com Canada

ARS Pharmaceuticals exec sells over $1.29 million in company stock By Investing.com - Investing.com UK

Ars Pharmaceuticals CEO sells over $1.29 million in company stock By Investing.com - Investing.com UK

ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 3.1% - MarketBeat

Merino closer to Arsenal debut - Tribal Football

Recent Insider Activity Could Benefit ARS Pharmaceuticals Inc (SPRY) - Knox Daily

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Down to $13.30 - MarketBeat

ARS Pharmaceuticals (NASDAQ:SPRY) Receives Overweight Rating from Cantor Fitzgerald - Defense World

Should investors be concerned about ARS Pharmaceuticals Inc (SPRY)? - US Post News

ARS Pharmaceuticals (NASDAQ:SPRY) Rating Reiterated by Cantor Fitzgerald - MarketBeat

ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why - MSN

Investors in cash trouble should check out ARS Pharmaceuticals Inc (SPRY) - SETE News

Ares Management raises over $3.3B of U.S. opportunistic real estate capital (NYSE:ARES) - Seeking Alpha

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $22.75 Consensus PT from Brokerages - MarketBeat

Quest Partners LLC Increases Holdings in Resideo Technologies, Inc. (NYSE:REZI) - Defense World

ARS Pharmaceuticals Inc [SPRY] stock for 1,149,775 USD was sold by Tanimoto Sarina - Knox Daily

How To Trade (SPRY) - Stock Traders Daily

ARS Pharmaceuticals Inc: Navigating a Turbulent Year, Up -23.45% from 52-Week Low - The InvestChronicle

We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow - Simply Wall St

There is no way ARS Pharmaceuticals Inc (SPRY) can keep these numbers up - SETE News

ARS Pharmaceuticals (SPRY): A Bull Case Theory - Yahoo Finance

ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference - GlobeNewswire

ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference - StockTitan

ARS Pharmaceuticals Inc (SPRY) did well last session? - US Post News

ARS Pharma seeks FDA nod for needle-free epinephrine By Investing.com - Investing.com Australia

ARS Pharma seeks FDA nod for needle-free epinephrine - Investing.com

ARS Pharma seeks FDA nod for needle-free epinephrine By Investing.com - Investing.com Canada

ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I - The Bakersfield Californian

ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg - GlobeNewswire

ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.) - StockTitan

Analyst Ratings For ARS Pharmaceuticals - Benzinga

ARS Pharmaceuticals (NASDAQ:SPRY) Stock Rating Reaffirmed by Cantor Fitzgerald - MarketBeat

Analytical Lens: Exploring ARS Pharmaceuticals Inc (SPRY)’s Financial Story Through Ratios - The Dwinnex

Insider Returns Down To US$660k As ARS Pharmaceuticals' Stock Dips 12% - Yahoo Finance

ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why - Yahoo Finance

ARS Pharmaceuticals Stock: A Decent Bet For Upside After Neffy Approval (NASDAQ:SPRY) - Seeking Alpha

ARS Pharmaceuticals Launches Pre-Ordering Services for - GlobeNewswire

ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First - The Bakersfield Californian

ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis - StockTitan

Short Interest in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expands By 21.6% - MarketBeat

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 2.9% - MarketBeat

Leerink Partnrs Comments on ARS Pharmaceuticals, Inc.'s Q4 2024 Earnings (NASDAQ:SPRY) - MarketBeat

Simile a SPRY